Sentinel node biopsy and axillary dissection in breast cancer: The evidence and its limits;Sentinel-node-biopsie und axilladissektion beim mammakarzinom: Evidenz und ihre grenzen

Deutsches Arzteblatt International

Volumn 111, Issue 14, 2014, Pages 244-249

  Janni, Wolfgang ^a   Kühn, Thorsten ^b   Schwentner, Lukas ^a   Kreienberg, Rolf ^a   Fehm, Tanja ^c   Wöckel, Achim ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b KLINIKUM ESSLINGEN   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; HUMAN; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; REVIEW; SENTINEL LYMPH NODE BIOPSY; ADJUVANT THERAPY; AXILLA; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; FEMALE; INCIDENCE; LYMPH NODE; LYMPH NODE METASTASIS; META ANALYSIS; MORTALITY; PATHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 84899543493     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0244     Document Type: Review

References (37)

1. Giuliano AE, Haigh PI, Brennan MB, et al.: Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18: 2553-9. (Pubitemid 30432521)
2. Helms G, Kühn T, Moser L, Remmel E, Kreienberg R: Schulter-Arm-Morbidität nach Sentinel-Node-Biopsie und kompletter Axilladissektion - Daten einer prospektiv randomisierten Studie. Senologie 2008; 5-A65.
3. Kuehn T, Vogl FD, Helms GV, et al.: Sentinel Node Biopsy is a reliable method for axillary staging in breast cancer: results from a large prospective German multiinstitutional trial. Eur J Surg Oncol 2004; 30: 252-9. (Pubitemid 38425641)
4. DiSipio T, Rye S, Newman B, Hayes S: Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncology 2013; 14: 500-15.
5. Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M: Multicentre study of detection and falsenegative rates in sentinel node biopsy for breast cancer. Br J Surg 2001; 88: 1644-8. (Pubitemid 33124244)
6. Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early stage breast carcinoma: a metaanalysis. Cancer 2006; 106: 416.
7. Krag D, Weaver D, Ashikaga T, et al.: The sentinel node in breast cancer a multicenter validation study. N Engl J Med 1998; 339: 941-6. (Pubitemid 28455095)
8. Tafra L, Lannin DR, Swanson MS, et al.: Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233: 5159.
9. Fleissig A, Fallowfield LJ, Langridge CI, et al.: Postoperative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95: 279-93.
10. Veronesi U, Paganelli G, Viale G, et al.: A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-53. (Pubitemid 36951366)
11. Kuehn T, Bembenek A, Decker T, et al.: A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103: 451-61.
12. Lyman GH, Giuliano AE, Somerfield MR, et al.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol 2005; 23: 7703-20. (Pubitemid 46291835)
13. Gampenrieder SP, Rinnerthaler G, Greil R: Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013; dx.doi.org/10.1155/2013/732047
14. Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB: Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006; 93: 129-32. (Pubitemid 43235258)
15. Smidt ML, Janssen CM, Kuster DM, Bruggink ED, Strobbe LJ: Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005; 12: 2933.
16. Veronesi U, Orecchia R, Zurrida S, et al.: Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 2005; 16: 383-8. (Pubitemid 40458313)
17. Zavagno G, Carcoforo P, Franchini Z, et al.: Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. Eur J Surg Oncol 2005; 31: 715-20. (Pubitemid 41194647)
18. Moebus V, Jackisch C, Lueck HJ, et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28: 2874-80.
19. AGO-Leitlinien - Arbeitsgemeinschaft Gynäkologische Onkologie.
20. Giuliano AE, McCall L, Beitsch P, et al.: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252: 426-32.
21. Kreienberg R, Albert SU, Follmann M, et al.: Interdisziplinäre S3-Leitlinie "Diagnostik, Therapie und Nachsorge des Mammakarzinoms" des Onkologischen Leitlinienprogrammes der DKG, Deutschen Krebshilfe und AWMF Zuckerschwerdtverlag 2012, http://www.awmf.org/uploads/tx-szleitlinien/032045OL- k-S3-Brustkrebs-Mammakarzinom-Diagnostik-Therapie-Nachsorge-2012-07.pdf
22. AWMF Regelwerk, www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk- offline.html (last accessed on 31 January 2014)
23. Gartlehner, G, Chapman, A, Strobelberger M, et al.: Vergleichende Wirksamkeit und Sicherheit von alleiniger Sentinel-Lymphknoten-Biopsie oder kompletter Axilladissektion bei Sentinel-positivem Mammakarzinom: Systematische Übersichtsarbeit 2011. www.krebsgesellschaft.de/download/s3-bk-update-2012- ol-evidenzbericht-prof.-gartlehner.pdf (last accessed on 31. January 2149
24. Glechner A, Wöckel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, Kreienberg R: Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 812-25.
25. Yi M, Giordano SH, Meric-Bernstam F, et al.: Trends in and outcomes from sentinel lymph node biopsy (SLNB) vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from SEER database. Ann Surg Oncol 2010; 17: 343-51.
26. Bilimoria KY, Bentrem DJ, Hansen NM, et al.: Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009; 27: 2946-53.
27. Galimberti V, Cole BF, Zurrida S, et al.: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305.
28. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N: Twentyfiveyear follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-75.
29. Martelli G, Boracchi P, De Palo M, et al.: A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow up. Ann Surg 2005; 242: 16.
30. Rudenstam CM, Zahrieh D, Forbes JF, et al.: Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 1093. J Clin Oncol 2006; 24: 337-44. (Pubitemid 46630451)
31. Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R: The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30year results of a randomised trial. Eur J Cancer 1999; 35: 1320-5. (Pubitemid 29397430)
32. Veronesi U, Galimberti V, Mariani L, et al.: Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005; 41: 231-7. (Pubitemid 40126955)
33. Fisher B, Wolmark N, Redmond C, Deutsch M, Fisher ER: Findings from NSABP protocol No. B-04: Comparison of radical mastectomy with alternative treatments. The clinical and biologic significance of medial-central breast cancers. Cancer 1981; 48: 1863-72. (Pubitemid 11022890)
34. Engel J, Emeny RT, Hölzel D: Positive lymph nodes do not metastasize. Cancer Metastasis Rev 2012; 31: 235-46.
35. Kuehn T, Bauerfeind I, Fehm T, et al.: Sentinel-lymph-node biopsy with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective multi-center cohort study. Lancet Oncol 2013; 14: 609-18.
36. Boughey JC, Suman VJ, Mittendorf EA, et al.: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-61.
37. Galimberti V, Cole BF, Zurrida S, et al.: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305.